2-Amino-46-Dimethoxypyrimidine CAS 36315-01-2 - China Factory, Suppliers, Manufacturers

2-Amino-46-Dimethoxypyrimidine CAS 36315-01-2, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

Trimagnesium Dicitrate Nonahydrate CAS 153531-96-5 Magnesium (Mg) 14.5%~16.4%

Saccharin Insoluble CAS 81-07-2 Purity >99.0% (HPLC)

2,3-Butanedione CAS 431-03-8 Purity >99.0% (GC)

Citric Acid Anhydrous CAS 77-92-9 Assay 99.5~100.5%

Dimethyl Dicarbonate (DMPC) CAS 4525-33-1 Purity ≥99.8% (HPLC) Food Additive Preservative

Maltol CAS 118-71-8 (3-Hydroxy-2-Methyl-4-Pyrone) Purity ≥99.0% (HPLC)

Top Selling Products

Related Blog
Reviews

Yellow phosphorus and phosphoric acid rose together

Yellow phosphorus and phosphoric acid rose together Yunnan-guizhou yellow phosphorus prices rose.Data show that the offer of 34500 yuan/ton at the beginning of the week has risen to 60,000 yuan/to...
Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models This forum focuses on the interdisciplinary and cutting-edge technologies...
The “Summit on COVID-19 Diagnostics & Treatment”

The “Summit on COVID-19 Diagnostics & Treatment” September 27-29, 2021 at China International Exhibition Center (Tianzhu New Hall), Beijing. The outbreak of Corona Virus Disease 2019 (...
Xi presents award to top scientists

President Xi Jinping, also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission, presents China’s top science award to a...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
New COVID treatments offer hope

Scientists around the world have made promising breakthroughs in developing a cure for COVID-19. Among new developments include antiviral pills and antibody compounds. As more countries look to ado...

2022.12.09 23:21:47
2022.10.22 00:04:42
2022.09.28 01:41:22
2022.08.08 03:16:46
2022.08.02 00:10:02
2022.02.04 11:53:15

2-Amino-46-Dimethoxypyrimidine CAS 36315-01-2 - China Factory, Suppliers, Manufacturers

Related Products

2-Amino-4,6-Dimethoxypyrimidine CAS 36315-01-2 Purity >99.0% (GC) Factory High Quality

Trimagnesium Dicitrate Nonahydrate CAS 153531-96-5 Magnesium (Mg) 14.5%~16.4%

Saccharin Insoluble CAS 81-07-2 Purity >99.0% (HPLC)

2,3-Butanedione CAS 431-03-8 Purity >99.0% (GC)

Citric Acid Anhydrous CAS 77-92-9 Assay 99.5~100.5%

Dimethyl Dicarbonate (DMPC) CAS 4525-33-1 Purity ≥99.8% (HPLC) Food Additive Preservative

Maltol CAS 118-71-8 (3-Hydroxy-2-Methyl-4-Pyrone) Purity ≥99.0% (HPLC)

Top Selling Products

Methyl Pivalate CAS 598-98-1 (Methyl Trimethylacetate) Purity >99.0% (GC) Factory

DL-Cysteine CAS 3374-22-9 Assay 98.0~102.0%

3-Bromophenylacetic Acid CAS 1878-67-7 Purity >98.0% (GC) High Quality

Z-Thr-OMe CAS 57224-63-2 Z-L-Threonine Methyl Ester Purity ≥98.0% (HPLC)

3-Bromoisonicotinic Acid CAS 13959-02-9 Purity >98.0% (HPLC)

5-Acetylsalicylamide CAS 40187-51-7 Purity >98.0% (HPLC)

Zoledronic Acid CAS 118072-93-8 Purity ≥99.7% API Factory High Quality

(R)-(-)-Methyl Mandelate ; Methyl D-(-)-Mandelate CAS 20698-91-3 High Purity

Glimepiride CAS 93479-97-1 Assay 98.0%~102.0% API Factory High Purity

Boc-Ile-OSu CAS 3392-08-3 Purity >98.5% (HPLC)

Lithium Bis(trifluoromethanesulphonyl)imide (LiTFSI) CAS 90076-65-6 Purity ≥99.9% Lithium Battery Electrolyte

Oxiracetam CAS 62613-82-5 Assay: 98.0~102.0% Nootropic

Yellow phosphorus and phosphoric acid rose together

Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

The “Summit on COVID-19 Diagnostics & Treatment”

Xi presents award to top scientists

Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

New COVID treatments offer hope

2022.12.09 23:21:47

2022.10.22 00:04:42

2022.09.28 01:41:22

2022.08.08 03:16:46

2022.08.02 00:10:02

2022.02.04 11:53:15

related search